These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 11330950

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
    Kim RJ, Peterson G, Kulp B, Zanotti KM, Markman M.
    Gynecol Oncol; 2005 May; 97(2):374-8. PubMed ID: 15863132
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
    Stathopoulos GP, Katis C, Tsavdaridis D, Dimitroulis J, Karaindros D, Stathopoulos J, Dimou E.
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):555-60. PubMed ID: 16520987
    [Abstract] [Full Text] [Related]

  • 28. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
    Tulpule A, Groopman J, Saville MW, Harrington W, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS.
    Cancer; 2002 Jul 01; 95(1):147-54. PubMed ID: 12115328
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.
    Cancer; 2002 Sep 15; 95(6):1265-73. PubMed ID: 12216094
    [Abstract] [Full Text] [Related]

  • 31. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
    Horiguchi J, Rai Y, Tamura K, Taki T, Hisamatsu K, Ito Y, Seriu T, Tajima T.
    Anticancer Res; 2009 Feb 15; 29(2):625-30. PubMed ID: 19331212
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F.
    Crit Rev Oncol Hematol; 2008 Jun 15; 66(3):229-36. PubMed ID: 18243011
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer].
    Kii T, Takiuchi H, Gotoh M, Kawabe S, Ohta S, Tanaka T, Kuwakado S, Nishitani H, Katsu K.
    Gan To Kagaku Ryoho; 2006 May 15; 33(5):621-4. PubMed ID: 16685160
    [Abstract] [Full Text] [Related]

  • 37. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, Alafaci E, Scimone A, Spano F, Spitaleri G.
    Oral Oncol; 2004 May 15; 40(5):525-31. PubMed ID: 15006626
    [Abstract] [Full Text] [Related]

  • 38. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 May 15; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I, Szánthó A, Mayer A, Thurzó L, Pulay T.
    Orv Hetil; 2003 May 11; 144(19):919-24. PubMed ID: 12809068
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.